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ABSTRACT 
Title 
Adherence of HIV/AIDS patients to antiretroviral therapy in a district hospital in Nankudu, 
Namibia. 
Okebie  CO MBBS 
Pather M.  MBChB (UCT); MFamMed (Stell); BSc Hons Medical Sciences (Stell); FCFP (SA) 
Background: 
Non-adherence to highly active  antiretroviral therapy (HAART) is a strong predictor of progression to 
AIDS and death. It remains the most important potentially alterable factor that determines treatment 
outcome. 
AIM: 
The main purpose of this study is to determine the current frequency of adherence to HAART in a major 
HIV/AIDS treatment center in Nankudu District and to identify the local factors contributing to non-
adherence. 
OBJECTIVES:   
To assess and measure the adherence to antiretroviral therapy. 
To assess and describe the defaulter rate 
To assess and describe the interruption rate 
To describe the local barriers to sub-optimal adherence in the sample patients 
Methods: 
The study was a descriptive survey of the below mentioned three methods used to assess adherence to 
HAART and the determination of local barriers to adherence. The three methods used to measure 
HAART adherence were: pill counts, pharmacy refill data and self-report. The participants CD4 counts 
and viral loads were also evaluated. It included a randomly selected sample of 225 adult patients 
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receiving HAART treatment in the Communication for Disease Control (CDC)-HIV clinic of Nankudu 
district hospital of Namibia.  
Results: 
A total of 90% of the patients had an adherence >95% comparable to those reported in most sub-Saharan 
Africa. The major local barriers to adherence  included: distance from clinic (100%), lack of food (100%), 
lack of money (100%), poverty (100%),  occupational factors-migration (100%), travel (81%), ran out of 
medicine (69%), too busy (69%), medication side effects (56%), felt better ( 56%) and too sick (50%). 
The major reasons given by the treatment defaulters were similar to those given by the treatment 
interrupters except for stigma (100%), compared to 19% for the treatment interrupter. 
Conclusion: 
The level of HAART adherence in the Communication Diseases Control (CDC)- HIV Clinic, of 
Nankudu District Hospital in Namibia is comparable to those reported in most sub-Saharan Africa, 
which is the recommended 95%. The pattern of non-adherence is characterized by treatment defaulters 
and interrupters. The study revealed that there were more treatment interrupters than defaulters. 
Financial constraints, travel, running out of ARV medicine, food insecurity, poverty, distance from the 
clinic, were the major reasons given by the treatment interrupters, while occupational factors, lack of 
transport, stigma, and long distance of the health facility were the major reasons given by the treatment 
defaulters. 
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BACKGROUND AND MOTIVATION 
Appropriate use of antiretroviral treatment (ART) has improved the health of many human 
immunodeficiency virus (HIV) positive individuals who otherwise may have died. Notably, the efficacy 
of any treatment depends on sustained high levels of adherence to ART. 
1,2,3,4,5
 ART regimens are often  
complicated and can include varying dosing schedules, dietary requirements, and adverse effects.
6
 
Different levels of adherence have been reported in several countries in sub-Saharan Africa and North 
America.
5
 In sub-Saharan Africa, concerns about adherence problems have been an important 
consideration in expanding access to antiretroviral therapy (ART).
5
 Reports have proved that adherence to 
ART is better in sub-Saharan Africa than in North  America.
7,5,8
 
Although reported barriers to adherence are consistent across multiple settings and countries, studies had 
shown adherence levels and the profile of factors that influence it differ by settings
9-11
 
Namibia is one of the Southern African countries that has one of the highest prevalence rates of 
HIV/AIDS infection which peaked at 22% in 2002 sentinel survey,
12
 but now has decreased to 18.8% in 
the 2010 sentinel survey.
13  
 The Kavango region in which the Center for Disease Control (CDC) HIV 
Clinic of Nankudu hospital is situated had a similar prevalence of 18.8% in the 2010 sentinel survey.
13 
Despite adequate knowledge of HIV/AIDS and ongoing counseling sessions given to patients on ART 
receiving treatment at the CDC clinic of the Nankudu Hospital, adherence problems still persist.
14
 This 
has necessitated the formal assessment of HAART in this area. To improve antiretroviral adherence, we 
conducted a cross- sectional survey of the social, cultural, personal, structural and economic determinants 
of treatment adherence. 
LITERATURE REVIEW 
The advent of highly active antiretroviral therapy (HAART) regimens have brought about a highly 
significant reduction in HIV related morbidity and mortality in recent years.
15  
Unlike treatment for most 
chronic conditions, ART requires very high levels of adherence for an indefinite period to achieve the 
desired results.
16
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Evidence shows that poor adherence to antiretroviral treatment regimens has serious consequences for 
HIV infected patients, including treatment failure, viral replication, the development of clinical 
complications and shortened survival.
17-19
 
This review focuses on the discussion and comparison of various measures of treatment adherence, and a 
description of barriers to and predictors of treatment adherence, and a commentary on strategies to 
improve treatment adherence.
 20 
Currently HAART adherence can be measured by researchers using the following methods: data obtained 
from patients, providers, pill bottles, pharmacy records, electronic devices, biochemical assays, or 
combinations of these sources. To date, there is no established “gold standard” for measuring adherence 20 
The abovementioned mentioned approaches have distinctive benefits and drawbacks. But, only the patient 
self report, pill bottles count, pharmacy records and electronic devices will be discussed below. 
Estimates of treatment adherence from patients’ self reports are less complex to obtain than other 
methods. It is subject to recall and/or social desirability bias. All forms of self-report inevitably 
overestimate adherence compared with other treatment adherence measures.
19,21
 
Treatment adherence can also be measured by having the pharmacist or a designee count the number of 
pills remaining in one bottle. Unfortunately, pill counts are time consuming and determining the date 
when the patient commenced the current prescription(s) can be difficult, especially when patients 
combine all their medications in one bottle. Although pill count is less subjective than self reporting, 
inaccuracies occur when patients remove pills from their   bottles without taking them (“pill dumping’’) 
to appear more adherent when counts occur.  Unannounced pill counts have been adopted to limit this 
behaviour. Patients may also forget their pill bottles, separate pills into weekly organizers, or use different 
formulations of the same medication that may appear to be different medications
22
  
The pharmacy based method examine the rate of refilling medications over a period of more than 2 
months.
23
This method is based on a straightforward premise that when a patient does not receive timely 
refills of a drug from the pharmacy, he or she is either not taking medications between refills or is missing 
doses such that a given prescription takes longer than it should. The strengths of this approach are that it 
is not susceptible to reporting bias or tampering and offers population based information. 
23
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Electronic monitors offer a more objective measure of treatment adherence than do self reports. However, 
the cost of these devices limits their use in non-research settings, and the caps can malfunction or get lost.  
Decanting (removing >1 dose at a time) or loosening the caps to make it easier to remove pills has been 
shown to be a common problem in studies using electronic monitors. 
24
 
 
Generally, the factors that influence adherence to antiretroviral therapy (HAART) fall into three 
categories namely: patient-related (psychosocial and educational) factors, patient- provider factors 
(interaction with physicians and other health workers and access to medications) and clinical factors ( pill 
burden, dosing frequency and adverse effects of medications).
25,26
  Physical and psychological distress 
amidst financial constraints and stigmatization as well as conflicting messages from health care 
providers  and religious authorities may form significant barriers to sustained HAART adherence 
and medical care. Furthermore, medication side effects, behavioral factors (forgetting doses, 
stopping medications when symptoms disappear) confidentiality, occupational factors, illiteracy, 
long distances to HIV/AIDS care centers may contribute to major barriers to HAART adherence. 
 
Defaulting or interruption of treatment is one of the most important problems in the management of 
HIV/AIDS. Low adherence can result in cross-resistance to other antiretroviral medications
. 27
which 
potentially interfere with future therapeutic option for those being treated and those who subsequently 
become infected with resistance virus.
28 
Ninety- five percent adherence to antiretroviral medication 
regimen is often needed to achieve optimal rates of viral suppression in people living with HIV/AIDS. 
Even so, there is often undetectable viral load in approximately 80% of patients.
 29
 Adherence level of 
95% implies that a patient taking a twice daily regiment cannot miss more than 3 doses per month. This 
can be more difficult than it might seem particularly if the need to refill prescriptions every month, to 
have medications available when working and traveling, and to avoid side effects of medication are 
considered.
30  
 
AIM: 
The main purpose of this study is to determine the current frequency of adherence to HAART in a major 
HIV/AIDS treatment center in Nankudu District and to identify the local factors contributing to non-
adherence. 
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OBJECTIVES:   
 
To assess and measure the adherence to antiretroviral therapy. 
 
To describe the local barriers to sub-optimal adherence in the sample patients 
 
To assess and describe the defaulter rate 
 
To assess and describe the interruption rate 
 
 
METHODS 
 
Study design: Descriptive cross-sectional survey  
 
Setting 
A descriptive cross-sectional survey was conducted over six months to assess and measure adherence rate 
and to identify those  local factors that impede on optimal HAART adherence among patients attending 
the Center for Disease Control (CDC)  HIV outpatient clinic of Nankudu hospital in Namibia. Nankudu 
District Hospital in Kavango region of Namibia, with a 120 bed capacity, serves as a referral hospital for 
four community health centers and 10 primary health care clinics. Its CDC-HIV clinic provides HAART 
services free of charge. When there are no complications, patients attend the clinic on a monthly basis for 
HAART  refill and every six months for CD4 count test plus other essential laboratory tests monitoring as 
well as viral load test six months after HAART initiation and when necessary. 
 
Sample selection 
CDC-HIV clinic had in its computerized database about 1500 registered patients on HAART programme 
by the first quarter of 2010. Based on the 1500 registered patients on HAART, a calculated 240 sample 
size was obtained. Included in the sample were male and female (18-60 years old) outpatients diagnosed 
to be having HIV/AIDS (using both laboratory and clinic data) that were attending HIV/AIDS   clinic 
between January 2006 and March 2010, and refilling their prescriptions in the pharmacy section of 
Nankudu District Hospital. All the patients had been on HAART and were regular at the clinic for not less 
than 6 months prior to the study and had consented to participate in the study. The study participants, who 
met the inclusion criteria, were randomly selected as they came to refill their prescriptions during the 
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Mon- Fri clinic days. Fifteen of the study participants who did not complete the study, due to relocation to 
a different region of the country were not included in the computed adherence data. Participants   
excluded  in the study sample, were those with a history of serious cardiovascular illness, diabetes and/or 
cancer (excluding non-melanoma skin cancer) within the previous 2 years.  The exclusion of people with 
chronic disorders was because the severity and stress of their medical conditions; in addition, to 
associated negative emotional factors might  compromise their ability to give voluntary informed consent 
 
Ethical considerations 
 
The Research question which has never been carried out in the region/districts, will identify barriers to 
optimal HAART adherence and make recommendations which will help the relevant health authority to 
draft   policy that will overcome the identified obstacles to HAART adherence in  HIV patients on 
treatment at the Center for Disease Control (CDC) HIV clinic of Nankudu District Hospital of Namibia. 
 
The planned design and methods were well thought-through; and the planned sample sizes and the 
statistical analysis plan were in accordance with the directives received from the statistical services of the 
University of Stellenbosch.  
 
The study population included: both female and male gender; those on treatment with antiretroviral 
medications for HIV infection; as well as, participants that speak English or the local language Kwangali. 
The randomly selected study population was not vulnerable in any way: being participants whose ages 
make them competent to consent. Patients were excluded if they have a history of serious cardiovascular 
illness, diabetes and/or cancer (excluding non-melanoma skin cancer) within the previous 2 years.  The 
exclusion of people with chronic disorders was because the severity and stress of their medical 
conditions; in addition, to associated negative emotional factors  might have compromise their ability to 
give independent informed consent. However, pregnant women have been included as study participants, 
since there were no risks to the foetus and the mother but rather for the health benefit and best interest of 
the mother and the foetus. 
 
No imaginable risks and discomfort were anticipated for the study patients.  However, any participant 
who  might have experienced discomfort , was anxious or afraid at any point of the study would have 
been withdrawn from the study and would have been referred to a counselor, to enable him/her to return 
to normal emotional state and  routine health care. 
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The research was submitted to the Health research ethics committee, University of Stellenbosch and the 
hospital management of my facility for independent ethical review and officially approved. 
 
Participant autonomy was respected by: adequate informed consent, confidentiality, truth telling and good 
communication. Confidentiality was achieved by ensuring the collection and storage of data had code 
numbers as a patient identification, but the key that linked the code number to the patient was kept by a 
third party that was not directly involved in the research.  
 
Privacy was protected by conducting the interviews in a separate office room in the hospital where the 
conversation could not be overheard. Participation was entirely voluntary and participants were free to 
withdraw without explanations and without compromise of their routine health care 
 
Instruments  
 
The standard structured questionnaire {validated Adult AIDS Clinical Trial Group Adherence Instrument 
(ACTG)}
 31 
was modified and used for the collection of socio-demographic and information on 
adherence. The questionnaire contained open –ended and/or closed questions. The questionnaire was 
piloted on 20 study participants and the resultant data were not included in the final computed data 
reported. 
 
Treatment variables were obtained from the medical records. Clinical variables such as patients HIV 
status , CD4 counts , viral load results were also obtained from patients’ medical records. Patient 
counseling was done for each patient every month when they came to refill their prescriptions using 
standard procedure.  
 
Operational definitions: 
 Adherence: With respect to HIV/AIDS care specifically, medication adherence has been defined 
as the ability of the people living with HIV/AIDS(PLWHA) to be  involved in choosing, starting, 
managing and maintaining a given therapeutic combination regimen to control viral (HIV) 
replication and improve immune function 
32
 
 Optimal adherence: This is the level of adherence needed to maximally suppress viral 
replication in patients receiving HAART estimated to be at least >- 95%.
29
 
 Treatment interrupter:  HAART patients that miss their treatment  for  more than  2 weeks and 
less than 8 weeks but were adherent to the medications when they had the medications.
33
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 Treatment defaulter:  HAART patients that miss  two consecutive clinic visits or had 
interrupted treatment for eight consecutive weeks.
33
 
 Virologic failure: This is defined in the Namibian national antiretroviral (ART) guideline as a 
viral load(VL)>1000copies/ml 24 weeks after starting HAART or viral rebound to> 
1000copies/ml on two consecutive measurements after a period of viral suppression.
33
 
 
Outcome measures 
 
Adherence to HAART medication was assessed at the end of each month for 6 months using pill 
counting, patient self-reporting and pharmacy refill medication records.CD4 count test was done at  the 
final (6
th
) month of the study to confirm or rule out  any immunological failure. Viral load test was done 
when there was immunological failure and/or clinical failure. 
 
In the first method, pharmacy medication records for patients were matched by the pharmacist against the 
not-yet-used medicines brought to the pharmacy by the patients as a routine for refill of prescriptions by 
patients and the number of doses that ought to have been taken that were missed were recorded. 
 
Patients self -reporting method was carried out as previously described by Weiser S, Wolfe W, Bangsberg 
D, Thior I, Gilbert P,  and Makhema J. Kebaabetswe P, Dickenson D,  Mompati K, Essex M, 
Marlink R. 26 After normal consultation, the consented patients were taken to a designated private room 
within the clinic where the interviews were conducted.
 
In this method, patients were interviewed with a 
standard questionnaire, about their adherence over the previous day, previous week and previous months 
successively in an attempt to minimize recall bias.  The principal researcher and other research assistants 
interviewed the participants in the local language of Rukwangali with the help of a trained assistant fluent 
in the local language. The questionnaire was a modified version of the validated Adult AIDS Clinical 
Trials Group
31 
 
In the pharmacy medication refill HAART patient records, the rate of HAART refill medications was 
determined every month for each patient through out the studied period. Each participant follow –up date 
for refill prescriptions was checked each month throughout the study period. In each of the methods, the 
average adherence was determined and the data compared with those reported from studies conducted in 
other parts of sub-Saharan Africa.
 34-39 
Access to medicines was evaluated by examining pharmacy records of antiretroviral drugs and other 
medicines (antibiotics, and multivitamins/haematinics) often prescribed by the attending physicians for 
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the patients. The average stock-out duration (SOD) for the medicines was evaluated as the average 
number of days in the 6 months study period, each medication was out -of –stock. In order to introduce 
availability of the medicines for each patient, stock out duration for patients in the treatment center 
SODpt and at home (SODph) were introduced as the average number of days per patient the required 
medicines could not be dispensed to each patient in the treatment center (SODpt) because of stock-out 
(SODpt) or available for use at home (SODph). Patients who ran out of their medicines at home were 
interviewed with the questionnaire on the reasons why the medicines were not available for use at home. 
The reasons for any stock- out of medicines in the treatment center were obtained from the pharmacy 
records. 
 
RESULTS  
 
Of the 240 patients recruited for the study, with written informed consent, 15 (6.25%) of them did not 
complete the study due to relocation to other regions of the country for employment and social reasons 
and were consequently excluded. Therefore, 225 (93.75%) study participants completed the study.  
 
Section 1 
 
Demographic and Treatment Data 
 
The demographic data are summarized in Table 1. The majority (65%) of the study participants were 
females, consistent with the prevalent statistics of more female enrolment in HAART treatment in the 
health facility. About 51% males and 18% females were married, 24% females and 3% males were 
widowed, 21% males and 44% female were single. While the same percentage of 15% of males and of 
females were cohabiting.  Christianity was their major religion. While as many as 25% of them had no 
dependants, some (11%) study participants had between 5 and 12 dependants. The majority of the study 
participants had primary education-67% males and 59% females respectively, while the rest of the study 
participants educational achievements were as stated- 33% males and 38% females had secondary 
education, 3% had no formal education and none of them (0.0%) had tertiary education.  About 41% 
males and 65% females were peasant farmers, while 88% were unemployed. Only 6% (3% males and 3% 
females) of the study participants were engaged in retail trading and none (0.0%) stated being a civil 
servant or self- employed. The majority of the study participants - 55% males and 85% females drank 
alcohol before HAART initiation as compared to- 10% males and 1% females that still drink alcohol after 
HAART initiation. About 14% of the males and 5% of the females had a history of smoking before 
HAART initiation, as compared to 6% males and 0% females that still smokes after HAART initiation. 
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Table 1.  Demographic data of the study participants  
 
           Characteristics                  Male (%)                  Female (%) 
 
                                       
Ages(y) 
Range 
18- 30 
30-49 
->50 
 
Total 
Grand total(226) 
 
            
 
              
               36     (46)  
               23     (30)  
               19     (24)  
 
               78    (100) 
 
 
                 
 
                  
                  85   (58)   
                  46   (31) 
                  16   (11) 
 
                147  (100) 
 
               Religion   
Christianity 
Traditional/no religion 
               70      (90) 
                 8      (10) 
                145   (99) 
                    2   (1) 
          Marital status   
Single 
Married 
Widowed 
Separated 
Divorced 
Cohabiting 
               16     (21)   
               40     (51) 
                 2     (3) 
                 5     (6) 
                 3     (4) 
               12     (15) 
                  44   (30) 
                  27   (18) 
                  35   (24) 
                  12   (8) 
                    7   (5) 
                  22   (15) 
      No. of 
dependants(adults 
&children 
  
 0 
1-2 
3-4 
5-10 
>10 
                6      (8) 
              13      (17) 
              14      (18) 
                2      (3) 
                1      (1) 
                  23   (17) 
                  20   (14) 
                  13   (9) 
                  10   (7) 
                    0   (0.0) 
 
     Level of education   
  No formal education 
  Primary  
  Secondary  
  Tertiary 
                0     (0.0) 
              52     (67) 
              26     (33) 
                0     (0.0) 
 
                   5    (3) 
                 86    (59) 
                 56    (38) 
                   0    (0.0) 
 
           Occupation   
   Peasant farmer 
   Retail trader 
   Self employed 
   Civil servant 
   Un-employed 
              32    (41) 
                2    (3) 
                0    (0.0) 
                0    (0.0) 
              44   (56) 
                 95   ( 65) 
                  5    (3) 
                  0    (0.0) 
                  0    (0.0) 
                 47   (32) 
      Substance habits:   
   Prior alcohol 
   Prior smoking 
   Current alcohol 
   Current smoking 
              43   (55) 
              11   ( 14) 
                8   (10) 
                5   (6) 
                125  (85) 
                    8   (5) 
                   2   (1) 
                   0   (0.0) 
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Section 2 
Clinical variables 
 
The clinical variables are summarized in tables 2- 4. The CD4 counts for 65% of the patients included in 
this study were higher than 200 cell/microlitre. The study participants with counts below 
50cells/microlitre were on the minority (11%). At the end of the six(6) months study period, 59% of the  
78 males and 63% of the  147 females  study participants  had a  much higher immunologic response with 
a CD count of >350cells/microlitres respectively, while as few as 1% male and 3% females(4%) had an 
immunologic failure with a  CD4count of <100cells/microlitres respectively. The  4% of the study 
participants who had immunologic failure, had their viral loads(VL) tested;  a concordance virologic 
failures of 3% and 1% (total 4%)were detected with the results of >1000-10000copies/ml and 
>10000copies/ml respectively.( VL <1000copies/ml  is undetectable according to the  current Namibian 
ART  national guideline).
33 
Out of this 4%  of the virologic failures, 3% are the treatment defaulters while 
1%  belong to  the treatment interrupters. 
 
Table 2. Gender distribution and baseline CD4count among study participants.  
 
         Variable                    Male  (%)                 Female (%) 
CD4 count (baseline) 
<50 
100-200 
>200 
 
Total 
 
                    20      (26) 
                    40      (51) 
                    18      (23) 
                     
                   78      (100) 
    
 
 
 
                   4     (3) 
                 15     (10) 
               128     (87) 
                
              147     (100) 
 
 
 
Table 3.  Gender Distribution and Immunological(CD4count) response evaluation among study 
participants on HAART 
       Variable                    Male (%)                 Female (%) 
CD4 count 
<100 
200-350 
>350 
 
                      1      (1) 
                    31     (40) 
                    46     (59) 
 
                   4           (3) 
                 51         (35) 
                 92         (63) 
Table 4.  Gender distribution and Viral Load response evaluation among study participants on 
HAART 
 
           Variable                 Male     (%)              Female      (%) 
Viral Load 
<1000copies/ml 
>1000-10000copies/ml 
>10000copies/ml 
 
                   77      (99)  
                     1      (1) 
                     0      (0.0) 
 
                 143       (97) 
                     3       (2) 
                     1       (1) 
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Section 3 
 
Treatment variables 
  
At the time of recruitment for the study, all the patients were on first line HAART regimen. However, 4% 
of the study participants were switched to second line HAART regimen of Tenovofir+ Zidovudine+ 
Lamivudine+Lopinavir  due to poor response to the first line medications (virologic failure)  at the end of 
the 4
th
 month of  the six months study period, while the rest of the study participants-99% males and 97% 
females  continued with their first  line therapy throughout the study period. The percentage proportions 
of  the study participants that used the 6 different first line antiretroviral medication combinations in the 
study were roughly as stated:- 45% females  and 52% males -Zidovudine/Lamivudine/Nevirapine, 19% 
females  and  19% males -Zidovudine/Lamivudine/Efavirenz,  18% females and 7 males-
Tenovofir/Lamivudine/Nevirapine,  6% females and 8% males -Tenovofir/Lamivudine/Efavirenz),  8% 
females and 8% males-Stavudine/Lamivudine/Nevirapine  and 4% females and 6% males -
Stavudine/Lamivudine/Efavirenz.  All the study participants received routine multivitamins while 79% of 
the study participants with a CD4 count of < 350cells/microlitre received routine cotrimoxazole 
prophylaxis.( patients with a CD4 count of<350 shall be placed on Cotrimoxazole prophylaxis- Namibian 
national ART guideline.
33
). 
 
Section 4 
Adherence to antiretroviral therapy 
 
The result of the assessment of adherence to HAART is summarized in Table 5 
A total of 90% of the study participants were adherent by self -report, based on the definitions of 
adherence which is, completing -> 95% of the prescribed doses each month. In addition, 7% of the study 
participants interrupted treatment, based on the definitions of treatment interruption which is, missed  
treatment  for  more than  2 weeks and less than 8 weeks but were adherent to the medications when they 
had the medications. In addition, 3% of the study participants defaulted in their treatment as defined 
which is, missed two consecutive clinic visits or had interrupted treatment for eight consecutive weeks. 
However, according to the pharmacist assessment of adherence of the study participants; 80% were 
adherent based on the definition of adherence as stated above, 12% defaulted in their treatment based on 
the definition of treatment defaulter as stated above, 7% interrupted their treatment based on the definition 
of treatment interruption as stated above. Although the estimates of treatment interruption by patient self-
report and pharmacist assessment were the same (7%); however, there were disagreement about which 
proportion of study participants were able to adhere to treatment and which proportion of study 
participants defaulted in treatment. We latter found  that, out of the 12%  of the study participants said to 
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have defaulted in their treatment by the pharmacist assessment, only 3%  truly defaulted  in  their 
treatment,  which is in agreement with the defaulter rate of 3% by patient self -report. This 3% that 
defaulted treatment were seasonal farm workers that usually temporarily migrate to harvest grapes in 
different farms in another distant regions of the country for a period of 3 to 5months.  The reason for their 
defaulting is as result of their inability to refill their medications due to multiple factors (summarized in 
Table 6b) ranging from: fear of the consequences of the disclosure (stigma-discrimination and/or loss of 
employment) to the farm owners of their reason for the hospital visit, long distance to the nearest health 
facility, lack of easy availability of transport and lack of money for the transport if the transport is found. 
The remaining 9% said to have defaulted treatment by the pharmacist assessment did not default 
treatment. We found out that 7% of them traveled and therefore missed their appointment with the 
pharmacist, but collected their refill medications at a nearby health facility. The remaining 2% choose to 
have their refill medications at the private health facilities for convenience and availability of funding. At 
last, these findings brought about the concordance in adherence and defaulter rates assessment by patient 
self- report and the pharmacist assessment.  
 
Table 5. Patients and Pharmacy reports on adherence 
 
                           Findings                        Numbers (%) 
Patient self-report of adherence(n=225)   
   
    Adherent* 
   Treatment defaulter! 
   Treatment interrupter+ 
                                                                 
 
 
                      203 (90) 
                         6  ((3) 
                       16  (7) 
                      
Pharmacist assessment of adherence(n=225) 
    
   Adherent* 
   Treatment defaulter! 
   Treatment interrupter+ 
                                                                  
 
 
                  181  (80)   
                    28  (12) 
                    16  (7) 
                     
* Defined as completing->95% of prescribed doses 
! missed  two consecutive clinic visits or had interrupted treatment for eight consecutive weeks.  
+ missed their treatment for  more than 2 weeks and less than 8 weeks but were adherent to the 
medications when they had the medications. 
 
Section 5 
 
Principal local barriers to HAART Adherence 
 
In assessing the local barriers to treatment adherence, both open-ended and structured questions were 
posed. The results of the local barriers to treatment adherence are summarized in Table 6a and 6b. The 
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commonest reasons given for interrupting treatment were lack of food (100%), lack of money (100%) and 
poverty (100%). Other reasons included: travel (81%), too busy (69%), ran out of medicine (69%), 
distance from the clinic (100%), side effects (56%), and felt better (56%) and too sick (50%). The 
commonest reasons given for defaulting treatment included: travel and migration (100%), stigma (100%),   
distance from the health facility (100%), ran out of medicine (100%), and lack of transport (100%) Others 
included: lack of finances (33%) and too busy (67%).  
 
Table 6a:   Local barriers to interrupting treatment.{treatment interrupters+(n=16)} 
 
                            Findings                            Number(%) 
       Lack of food                              16  (100) 
       Ran out of medicine                              11  (69) 
       Travel                              13   (81) 
       Side effects                                9   (56) 
       Too busy                               11  (69) 
       Distance from clinic                              16   (100) 
       Too sick                                8   (50) 
       Misunderstood doctor                                5   (31) 
       Stigma                                3   (19) 
       Alcohol                                1   (6) 
       Felt better                                9   (56) 
       Stresses at home/work                                1   (6) 
       Too many pills                                1   (6) 
       Poverty                              16   (100) 
       Lack of money                              16   (100) 
+ missed their treatment for more than 2 weeks and less than 8 weeks but were adherent to the 
medications when they had the medications. 
 
Table 6b: Local barriers to defaulting treatment { treatment defaulters!(n=6)} 
               Findings                                                          Numbers (%) 
       Finances                           2  (33) 
       Ran out of medicine                           6  (100) 
       Travel and migration                           6  (100) 
       Too busy                           4  (67) 
       Distance from hospital                           6  (100) 
       Stigma                           6  (100) 
      Lack of transport                           6  (100) 
! missed two consecutive clinic visits or had interrupted treatment for eight consecutive weeks. 
 
Section 6 
 
Access to medicines 
 
In the CDC-HIV clinic, patients receive ARVs free of charge. The average stock out duration for each of 
the antiretroviral medications, multivitamins and or haematinics/ Cotrimoxazole often prescribed for the 
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patients during the 6 months period was zero. Similarly, the mean number of days the medications could 
not be dispensed in the clinic was zero. However, 69% of the treatment interrupters ran out of their 
medicines at home while 100% of treatment defaulters ran out of their medicine, when they migrated for 
their seasonal harvesting of grapes in other distant regions of the country. Lack of money for transport 
(100%) and too busy (69%) were the reasons given by the treatment interrupters, while lack of money 
(33%), unavailability of transport (100%), and too busy (67%) were among the reasons given by the 
treatment defaulters. 
 
 
DISCUSSION 
 
The data suggest that HAART adherence rates among the patients studied are comparable with HAART 
adherence rates in most sub-Saharan Africa.
34-37 
. However, in contrast to this survey findings, some 
studies in few sub-Saharan Africa reported a lower adherence rates among their study participants.
38,39 
This result is consistent with reports that, although reported barriers to adherence are consistent across 
multiple settings and countries, the adherence levels and the profile of factors that influence it differ by 
settings.
9-11
 
 
Measuring the adherence by patient self-report, pill counting, and pharmacy refill medications  and 
validated by CD4 count and viral load testing, showed that 90% of the patients were adherent with 95% 
of prescribed doses. Patients in this study had to overcome great odds (they lacked funds for transport, 
food insecurity, not easily availability of transport etc.) to adhere to treatment by often using carts driven 
by cows for transport to the clinic, often had to travel great distances by trekking on their feet at the 
danger of wild animals, to the CDC-HIV clinic to receive HAART medications, borrow money for 
transport and take medications without eating food. The results suggested by this study may be attributed 
mostly to the existence of excellent provider-client interaction in the CDC-HIV clinic.
14
 Evidence suggest 
that good counseling at an HIV clinic is important in improving adherence.
40
 Randomized controlled trials 
in Europe and the United States have also confirmed that dedicating time to individualized counseling and 
education increases patients’ sense of self-worth and efficacy.41-43 
 
For many patients, optimal adherence to antiretroviral therapy is often difficult to achieve for reasons 
ranging from patient factor to patient-health professionals relationship and clinical factors
.44,25,26 
Most of 
the factors identified in our study for treatment interruption and defaulting (financial constraints, 
medication adverse effects and occupational factor) have been reported in previous studies carried 
out.
45,28,46
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We also found that the two groups of non-adherent patients {treatment interrupters (7%) and the 
treatment defaulters(3%)} were overall 10%.   The commonest reasons for both interrupting and 
defaulting treatment were due to varying degrees of poverty (lack of money, lack of food and inability to 
afford medication) for varying periods of time the overall socio-economic situations ( as defined: lack of 
money, poverty and lack of food) and inability to afford medications for varying period of time 
 
Although the patients studied received free antiretroviral medications, the positive effect of free treatment 
is often offset by indirect transportation costs in areas in which the patients live far away from health 
facilities. This is consistent with findings in other studies on patients that received free antiretroviral 
medication.
47 
 
The decentralization of HAART services and task shifting to the primary health care centers and clinics 
will alleviate the patients’ problems of lack of transport, lack of money for transport, depleted medication 
stock, too busy, long distance to the clinic, as well as alleviate the problems of capacity at the CDC-HIV 
clinic and various other major HAART clinic centers. This is consistent with the findings of studies done 
in most major HAART clinics centers in South Africa.
48-50 
 
There is now considerable evidence across Africa of the feasibility of integrated district-based approaches 
that achieve universal access while maintaining quality and outcome.
51-53
However, a rapid transfer of 
large numbers of patients can overwhelm minimally staffed health centers and clinics, if appropriate steps 
are not taken. In addition, to the increased workload, clinic staff may not feel confident enough to carry 
out their new responsibility, particularly if training and supervision mechanisms are not adequately 
provided. Furthermore, providing HAART at the primary health care clinic level increases the number of 
entry points to care while the greater proximity of services encourages retention in care.
49
 
 
Overall, the virologic failure was present in only 4% of the study participants, a much lower proportion 
than the average rate in South Africa, which ranges between 10% and 16%.
 55 
Not surprisingly, the 
proportion of patients with virology failure were present only among both groups of HAART non-
adherent (treatment interrupters and defaulters) resulting to adherence levels of less than 95%, with its 
associated consequences of the susceptibility to virologic failure. 
 
Short-term and long-term adverse reactions (can be early and transient or evident with more prolonged 
use) have been identified with all of the available antiretroviral agents.
 32
 The occurrence of side effects 
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was a common regimen factor affecting adherence in our study, similar to previous findings 
elsewhere.
51,56 ,46, 28
 
 
HIV stigma was more in the treatment defaulters than the treatment interrupters. A total of 100% of 
treatment defaulters believed that stigma impeded their ability to take treatment in contrast to 19% of 
treatment interrupters.  Other factors that were predictive of non-adherence were ‘being too sick’ (50%) 
and were ‘hospitalized’ in a traditional healing home as well as ‘felt better’ (56%).  
 
The strength of our study was to corroborate patient self -report of adherence with CD4 cell count and 
viral load responses. The weaknesses of our study were not ascertaining why stigma was more in the 
treatment defaulters than the interrupters. In addition, we did not ascertain the degree of  the repercussions 
of stigma on the  study participants  as well as not determining if the following factors-, educational 
status, marital status, number of dependants, psychological distress, adverse life events, religion and types 
of occupation affected their  HAART adherence. These weaknesses will serve as a stimulus for future 
research in this setting. 
 
 Our limitations-financial constraints and logistical barriers impacted negatively on the sample size. 
Consequently, the patients in our study may not be a true representative of the broader population of HIV 
– positive  individual. Another limitation of this study is that we were unable to carry out  HIV viral load 
test on all study participants because the National guideline stated only those patients with clinically 
and/or immunological  evidence of failure should have their viral load tested, Consequently, the study 
may have underestimated the percentage of patients with virologic failure. 
 
 
CONCLUSION 
 
The performance of the CDC-HIV clinic in Nankudu district hospital in relation to HAART adherence 
was good. It is comparable to the levels previously reported in most sub-Saharan Africa. Financial 
constraints, long distances to the clinic medication side effects, confidentiality, occupational 
factors/migration and stigmatization were the major factors accounting for non-adherence.  The pattern of 
adherence among the studied population, characterized by treatment defaulters and interrupters rather 
than day to day adherence, reflects the presence of socio-economic effects, medication adverse effects and 
structural barriers.  
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RECOMMENDATIONS 
 
Programs (decentralization of HAART services to the primary health clinic and health centers) that will 
take medicines near the   door step of the poor patients are recommended.  Moreover, medication related 
factors can be remedied by the selection and procurement of ARVs with a better frequency of 
administration and side-effects profile. Furthermore, three – six monthly supply of medications will 
remedy the situation of those patients that encounter great difficulty in refilling their medications. Equally 
important, improving their socio-economic situations and minimizing identified structural  barriers will 
enhance optimal HAART adherence These recommended strategies, if implemented, should improve 
adherence and, consequently, treatment outcomes for patients receiving therapy in the CDC-HIV clinic 
and other major HAART clinic centers in the country. 
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ANNEXURE 
 
ANNEXURE 1 (Information letter)       
 
 
PARTICIPANT INFORMATION LEAFLET  
 
 
TITLE OF THE RESEARCH PROJECT:  Adherence of HIV/AIDS patients to antiretroviral 
therapy in a district hospital in Nankudu, Namibia 
 
REFERENCE NUMBER:NO9/10/286 
 
PRINCIPAL INVESTIGATOR: Dr Okebie C.O 
 
ADDRESS: P/BAG 2099,Rundu, Kavango Region, Namibia 
 
CONTACT NUMBER:00264813009523 
 
E-MAIL : mmerifechris@yahoo.com 
 
You are being invited to take part in a research project.  Please take some time to read the information 
presented here, which will explain the details of this project.  Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand.  It is very important that you are 
fully satisfied that you clearly understand what this research is all about and how you could be involved.  
Also, your participation is entirely voluntary and you are free to refuse to participate.  If you say no, this 
will not affect you negatively in any way whatsoever.  You are also free to withdraw from the study at 
any point, even if you do agree to take part. Equally important, any member of the research team can 
withdraw you, from further participation in the study, if you refuse to answer the questions, anxious or are 
afraid. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University as 
well as by the Namibia Ministry of Health and Social Welfare services and will be conducted 
according to the ethical guidelines and principles of the international Declaration of Helsinki, South 
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African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
 
Detailed information of the Research: 
 
The study will be conducted at the Center for Disease Control (CDC) HIV clinic of the Nankudu Hospital 
of Namibia. Its aim is to determine the current frequency of adherence to ART in a major HIV/AIDS 
treatment center in Nankudu District and to identify the local factors contributing to non-adherence. 
 
 
The method will involve face to face interviewing  of  each of  the 240  consenting participants (that will 
be recruited over a six (6) month period) with  a self report questionnaire(response form) during clinic 
attendance. In addition, to the questionnaire, other important participants information will be gotten from 
the pharmacy medication records and the participants computer data base. 
 
A total of 240 participants (members) will be selected in a random (chance) manner, that is, any 
participant has an equal chance of being selected to participate in the study..  
The chosen random sample will be a representative of the entire patients on the antiretroviral tablets. 
 
It is the responsibility of this health facility to promote health and prevent disease as well as to treat 
illness when it occurs. We want to find out about the factors that may affect people’s willingness not to 
take antiretroviral tablets as advised. Since we cannot select all on antiretroviral tablets to help us to 
achieve this, therefore, you have been selected in this regard. You can help us to achieve this by filling the 
self report questionnaire (response form) given.   
 
The information you give will help us to care better for   you, and other present and future patients from 
within   and outside the community that attend the hospital.  
 
You will not be exposed to any risk or harm during and after the research. 
 
You will be accordingly informed at any point of the study any new important information that may arise 
as the research is going on and the informed consent(permission) form will be changed, where necessary 
to include this information.. 
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The information given will be handled in strict confidence and only by authorized members of the 
research staff. No participant will be identified or mentioned in particular in any reports or publications. 
Study monitors may need to inspect the research records, if need be. Research report will be made 
available to the hospital authority and the state policy makers for appropriate action 
 
You will not be paid for taking part in the study, neither, will you be involved in any cost, if you take 
part. 
 
The contact details of the committee for Human research: Division for research Development and Support  
at University of Stellenbosch, Cape town-South Africa(+27219389207) for  any further queries. 
 
My contact details   are stated above and my cell phone number is 0813009523 if you have any further 
question or encounter any problems. 
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ANNEXURE 2 (Questionnaire)        
 
Modified  Adult AIDS Clinical Trials Group Questionnaire(A-H) 
 
 
 
A. What is your age?  (Tick one box) 
 
 
     1. 18-30 
 
 
 
 
      2. 30-49 
 
 
 
 
      3. _>50 
 
 
 
    
   
 
 
   
  
 
B. What is your sex? ( Tick one box) 
 
 
      1.  Male  
 
       
    
 
                  2. Female     
  
  
 
 What is your religion?   (Tick one box) 
 
            
                         
                           1   Christianity  
 
 
 
                            2.    Islam 
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                            3 Traditional 
 
                             
 
                            4  No  religion     
 
 
 
 
 
 
D. These last questions ask about your background. 
 
1. What is the highest level of education you have completed? (check one) 
 
•0 Primary School 
•1 Secondary School 
•2 2 years of college  / Technical school training 
•3 University (BA or BS) 
•4 Master’s degree 
 
 
 
2.What is  your occupation?  (Tick one box) 
 
 
 
                            1. Business Executive 
 
 
 
 
                            2.  Civil Servant 
 
 
 
 
                            3.  Trader 
                        
 
 
 
                          4.    Self-employed 
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                          5.  Peasant farmer 
     
 
                         
                           6.  Unemployed                        
 
 
                              
 
 
 
 
 
3. What is your marital status? (Tick one box) 
 
 
 
                          1.  Married       
 
 
 
 
                           2. Cohabiting 
 
 
 
 
                           3. Widowed 
 
 
 
 
                            4. Separated 
 
 
 
 
                          5 Divorced 
 
 
 
                           6. Single 
 
 
 
4. Do you have any dependants (Adult and Children)? •1 Yes •2 No 
If Yes, how many live with you? •• 
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E.   People have various health habits. The following questions ask about your alcohol and smoking 
habits, past and current 
 
Ei. Please check “Yes” or “No” for each question. 
a. •1 Yes •2 No Have you ever drank alcohol? 
 
b. •1 Yes •2 No Have you ever been involved in smoking (cigarettes, marijuana, cocaine, etc) 
 
Eii. Are you currently taking Alcohol? •1 Yes •2 No 
 
Eiii. Are you currently smoking?         •1 Yes •2 No 
 
F. When was the last time you missed any of your medications? Check one box 
 
•5 Within the past 4 days 
•4 Within the past week 
•3 2-4 weeks ago 
•0 Never skip medications or 
not applicable 
 
G. People may miss (interrupt) taking their medications for various reasons. Here is a list of 
possible reasons why 
you may miss taking your medications.  
 
 
                                                                                                   YES                NO                
 
1.  Were away from home(travel)?                                                  
 
2.  Too busy with other things?                                                      
 
3.  Had too many pills to take?                                                      
 
4.  Wanted to avoid side effects?                                                  
 
5.  Stigma a barrier?  
Reason that stigma is a barrier: 
5i Isolation 
 
5ii loss of employment 
 
5iii Discrimination 
 
5iv Divorce   
 
5v. Others-                                              
  
 
6.  Distant from clinic?                                                                
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7.  Felt sick or ill?                                                                           
 
8.  Lack of food?                                                                      
 
9.  Misunderstood Doctor?                                                                 
 
10. Ran out of ARV medicine at home?    
     Why: 
10i  
 
10ii 
 
10iii 
 
10iv                                                         
 
11. Stop when asymptomatic(felt better)?                                          
 
12. Stresses at home/work?                                                    
 
13. Poverty?                                                                                  
 
14.Lack of money?                                                                  
 
18 Alcohol ?          
 
19 Other reasons:-                                                                                               
 
H. People may miss dosages of ARV medicine for more than two months(treatment defaulters) for 
various reasons. Here is a list of possible reasons why that may happen. 
 
 
                                                                   Yes                 No 
  
1. Lack of finance? 
 
2. Too busy? 
If yes, state reasons: 
2i 
 
2ii 
 
        3. Travel/migration? 
 
  4. Distance from hospital? 
 
  5. Lack of transport? 
 
   
 
6. Ran out of medicine? 
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      If yes, state reasons: 
6I 
 
6ii 
 
   
7. Stigma? 
     If yes, state reasons: 
         7i Loss of employment 
          
         7ii Discrimination 
 
         7iii Divorce 
   
         7ivOther reasons- 
 
 
  8. Too sick? 
 
  9. Felt better? 
 
 10.Other reasons: 
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ANNEXURE 3 (Consent forms)        
                                                     CONSENT (permission) FORMS 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study 
entitled :  Adherence of HIV/AIDS patients to antiretroviral therapy in a district hospital in Nankudu, 
Namibia 
 
I declare that: 
 
 I have read or had read to me this information and consent(permission) form and it is written 
in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been forced to take 
part. 
 I may choose to leave the study at any time and will not be punished or discriminated in any 
way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher feels 
it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 
 ............................................................................  .........................................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
 I did/did not use a interpreter.  (If a interpreter is used then the interpreter must sign the 
declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2009. 
 
 ............................................................................  .........................................................................  
Signature of investigator Signature of witness 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the local language medium of Kwangali. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2009. 
 
 
 ............................................................................  .........................................................................  
Signature of interpreter       Signature of  Witness 
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ANNEXURE 4 (Raw data depicting the results of the questionnaires)  
 
Table 1.  Demographic data of the study participants  
 
           Characteristics                  Male (%)                  Female (%) 
 
                                       
Ages(y) 
Range 
18- 30 
30-49 
->50 
 
Total 
 
            
 
              
               36     (46)  
               23     (30)  
               19     (24)  
 
               78    (100) 
 
 
 
 
 
                 
 
                  
                  85   (58)   
                  46   (31) 
                  16   (11) 
 
                147  (100) 
 
               Religion   
Christianity 
Traditional/no religion 
               70      (90) 
                 8      (10) 
                145   (99) 
                    2   (1) 
          Marital status   
Single 
Married 
Widowed 
Separated 
Divorced 
Cohabiting 
               16     (21)   
               40     (51) 
                 2     (3) 
                 5     (6) 
                 3     (4) 
               12     (15) 
                  44   (30) 
                  27   (18) 
                  35   (24) 
                  12   (8) 
                    7   (5) 
                  22   (15) 
      No. of 
dependants(adults 
&children 
  
 0 
1-2 
3-4 
5-10 
>10 
                6      (8) 
              13      (17) 
              14      (18) 
                2      (3) 
                1      (1) 
                  23   (17) 
                  20   (14) 
                  13   (9) 
                  10   (7) 
                    0   (0.0) 
 
 
 
 
 
     Level of education   
  No formal education 
  Primary  
  Secondary  
  Tertiary 
                0     (0.0) 
              52     (67) 
              26     (33) 
                0     (0.0) 
 
                   5    (3) 
                 86    (59) 
                 56    (38) 
                   0    (0.0) 
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           Occupation   
   Peasant farmer 
   Retail trader 
   Self employed 
   Civil servant 
   Un-employed 
              32    (41) 
                2    (3) 
                0    (0.0) 
                0    (0.0) 
              44   (56) 
                 95   ( 65) 
                  5    (3) 
                  0    (0.0) 
                  0    (0.0) 
                 47   (32) 
      Substance habits:   
   Prior alcohol 
   Prior smoking 
   Current alcohol 
   Current smoking 
              43   (55) 
              11   ( 14) 
                8   (10) 
                5   (6) 
                125  (85) 
                    8   (5) 
                   2   (1) 
                   0   (0.0) 
 
 
 
Table 2. Gender distribution and baseline CD4 count among study participants.  
 
         Variable                    Male  (%)                 Female (%) 
CD4 count (baseline) 
<50 
100-200 
>200 
 
Total 
 
                    20      (26) 
                    40      (51) 
                    18      (23) 
                     
                   78      (100) 
    
 
 
 
                   4     (3) 
                 15     (10) 
               128     (87) 
                
              147     (100) 
 
 
 
 
 
Table 3.  Gender Distribution and Immunological (CD4count) response evaluation among study 
participants on HAART 
  
       Variable                    Male (%)                 Female (%) 
CD4 count 
<100 
200-350 
>350 
 
                      1      (1) 
                    31     (40) 
                    46     (59) 
 
                   4           (3) 
                 51         (35) 
                 92         (63) 
   
 
 
Table 4.  Gender distribution and Viral Load response evaluation among study participants on 
HAART 
           Variable                 Male     (%)              Female      (%) 
Viral Load 
<1000copies/ml 
>1000-10000copies/ml 
>10000copies/ml 
 
                   77      (99)  
                     1      (1) 
                     0      (0.0) 
 
                 143       (97) 
                     3       (2) 
                     1       (1) 
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Table 5. Patients and Pharmacy reports on adherence 
 
                           Findings                        Numbers (%) 
 Patient self-report of adherence(n=225)   
   
    Adherent* 
   Treatment defaulter! 
   Treatment interrupter+ 
                                                                 
 
 
                      203 (90) 
                         6  ((3) 
                       16  (7) 
                      
 Pharmacist assessment of adherence(n=225) 
    
   Adherent* 
   Treatment defaulter! 
   Treatment interrupter+ 
                                                                  
 
 
 
                  181  (80)   
                    28  (12) 
                    16  (7) 
                     
 
 
 
 
 
Table 6a:   Local barriers to interrupting treatment.{treatment interrupters+(n=16)} 
 
                            Findings                            Number(%) 
       Lack of food                              16  (100) 
       Ran out of medicine                              11  (69) 
       Travel                              13   (81) 
       Side effects                                9   (56) 
       Too busy                               11  (69) 
       Distance from clinic                              16   (100) 
       Too sick                                8   (50) 
       Misunderstood doctor                                5   (31) 
       Stigma                                3   (19) 
       Alcohol                                1   (6) 
       Felt better                                9   (56) 
       Stresses at home/work                                1   (6) 
       Too many pills                                1   (6) 
       Poverty                              16   (100) 
       Lack of money                              16   (100) 
+ missed their treatment  for  more than  2 weeks and less than 8 weeks but were adherent to the 
medications when they had the medications. 
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Table 6b: Local barriers to defaulting treatment { treatment defaulters!(n=6)} 
 
               Findings                                                          Numbers (%) 
       Finances                           2  (33) 
       Ran out of medicine                           6  (100) 
       Travel and migration                           6  (100) 
       Too busy                           4  (67) 
       Distance from hospital                           6  (100) 
       Stigma                           6  (100) 
      Lack of transport                           6  (100) 
! miss two consecutive clinic visits or had interrupted treatment for eight consecutive weeks. 
 
 
 
 
 
ANNEXURE 5 (Questionnaire summary)  
 
The modified AIDS Clinical Trials Group questionnaire (AACTG) used in this survey is a self- reported 
questionnaire instrument to ascertain adherence information to antiretroviral medications among the study 
participants. This adherence instrument asked study participants about their ARV adherence over the 
previous day, previous week and previous months. It also asked closed and open ended questions; in 
addition to questions on the background of the study participants, in order to identify local barriers to 
ARV adherence. 
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